Neuberger Berman Group
IOVA icon

Neuberger Berman Group’s Iovance Biotherapeutics IOVA Stock Holding History

Neuberger Berman Group’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$164K Buy
46,659
+7,587
+19% +$24.3K ﹤0.01% 2025
2025
Q4 		$107K Buy
39,072
+5,605
+17% +$13K ﹤0.01% 2011
2025
Q3 		$72.6K Buy
33,467
+589
+2% +$1.39K ﹤0.01% 1985
2025
Q2 		$56.5K Sell
32,878
-1,121
-3% -$2.79K ﹤0.01% 1987
2025
Q1 		$113K Buy
33,999
+8,879
+35% +$45.8K ﹤0.01% 1871
2024
Q4 		$186K Buy
25,120
+14,716
+141% +$136K ﹤0.01% 1806
2024
Q3 		$97.7K Buy
10,404
+370
+4% +$3.51K ﹤0.01% 1842
2024
Q2 		$80.5K Buy
+10,034
New +$108K ﹤0.01% 1822
2021
Q2 		– Sell
-398,484
Closed -$12.6M – 1791
2021
Q1 		$12.6M Buy
398,484
+341,409
+598% +$14.2M 0.01% 784
2020
Q4 		$2.65M Sell
57,075
-53,000
-48% -$2.1M ﹤0.01% 1057
2020
Q3 		$3.62M Buy
110,075
+15,000
+16% +$460K ﹤0.01% 928
2020
Q2 		$2.61M Buy
95,075
+59,975
+171% +$1.97M ﹤0.01% 958
2020
Q1 		$1.05M Buy
+35,100
New +$930K ﹤0.01% 1086
2018
Q3 		– Sell
-74,000
Closed -$947K – 1659
2018
Q2 		$947K Buy
+74,000
New +$1.08M ﹤0.01% 1247

Other funds holding IOVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

Neuberger Berman Group's IOVA Position: Q1 2026 in Review

Neuberger Berman Group increased its Iovance Biotherapeutics (IOVA) stake by 19% in Q1 2026, buying an estimated $24.3K and bringing the position to 46,659 shares worth $164K. The position accounts for ﹤0.01% of the portfolio, ranked #2025.

Neuberger Berman Group first reported a position in IOVA in Q2 2018 and has held it in 14 quarters since. The position peaked at $12.6M in Q1 2021. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

  • Neuberger Berman Group held 46,659 shares of Iovance Biotherapeutics worth $164K as of Q1 2026.
  • Neuberger Berman Group bought 7,587 Iovance Biotherapeutics shares in Q1 2026, an estimated $24.3K.
  • Iovance Biotherapeutics made up ﹤0.01% of Neuberger Berman Group's portfolio in Q1 2026, its #2025 holding.
  • Neuberger Berman Group first reported a position in Iovance Biotherapeutics in Q2 2018 and has held it in 14 quarters since.
  • Neuberger Berman Group's Iovance Biotherapeutics position peaked at $12.6M in Q1 2021.
  • 285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on Neuberger Berman Group's 13F filing for Q1 2026, filed 14 May 2026.